Prenatal screening for Down syndrome in Australia: Costs and benefits of current and novel screening strategies

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 53, Issue 5, 2013, Pages 425-433

  O'Leary, Peter ^a   Maxwell, Susannah ^a   Murch, Ashleigh ^b,c   Hendrie, Delia ^a,d  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

antenatal screening; Down syndrome; economic analysis; noninvasive prenatal testing; policy

Indexed keywords

ARTICLE; AUSTRALIA; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; MEDICAL AUDIT; NONINVASIVE PRENATAL TESTING; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTENATAL SCREENING; DOWN SYNDROME; ECONOMIC ANALYSIS; NONINVASIVE PRENATAL TESTING; POLICY;

ABORTION, SPONTANEOUS; COST-BENEFIT ANALYSIS; DECISION TREES; DNA; DOWN SYNDROME; FEMALE; HUMANS; MODELS, ECONOMIC; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY, HIGH-RISK; PRENATAL CARE; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; WESTERN AUSTRALIA;

EID: 84885143014     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/ajo.12136     Document Type: Article

References (44)

1. O'Leary P, Breheny N, Dickinson JE, et al,. First trimester combined screening for Down syndrome and other fetal anomalies in Western Australia. Obstet Gynecol 2006; 107: 869-876.
2. Maxwell S, Brameld K, Bower C, et al,. Socio-demographic disparities in the uptake of prenatal screening in Western Australia. Aust N Z J Obstet Gynaecol 2011; 51: 9-16.
3. Reid KP, Gurrin LC, Dickinson JE, et al,. Pregnancy loss rates following second trimester genetic amniocentesis. Aust N Z J Obstet Gynaecol 1999; 39: 281-285.
4. Jaques A, Collins VR, Muggli EE, et al,. Uptake of prenatal diagnostic testing and the effectiveness of prenatal screening for Down syndrome. Prenat Diagn 2010; 30: 522-530.
5. Bianchi D, Platt LD, Goldberg JD, et al,. MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group: Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119: 890-901.
6. Palomaki G, Kloza EM, Lambert-Messerlian GM, et al,. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med 2011; 13: 913-920.
7. Palomaki G, Deciu C, Kloza EM, et al,. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: An international collaborative study. Genet Med 2012; 14: 296-305.
8. Ashoor G, Syngelaki A, Wagner M, et al,. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206: e1-e5.
9. Norton M, Brar H, Weiss J, et al,. Non-invasive chromosomal evaluation (NICE) study: Results of a multicenter, prospective, cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207: e1-e8.
10. Bianchi D,. From prenatal genomic diagnosis to fetal personalized medicine: Progress and challenges. Nat Med 2012; 18: 1041-1051.
11. Chiu R, Chan KC, Gao Y, et al,. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 2008; 105: 20458-20463.
12. Liang D, Lv W, Wang H, et al,. Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. Prenat Diagn 2013; 33: 409-415.
13. Ashoor G, Syngelaki A, Wang E, et al,. Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound Obstet Gynecol 2013; 41: 21-25.
14. Chen E, Chiu RW, Sun H, et al,. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS ONE 2011; 6: e21791.
15. Chiu R, Akolekar R, Zheng YW, et al,. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: Large scale validity study. BMJ 2011; 342: C7401.
16. Dan S, Wang W, Ren J, et al,. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factors. Prenat Diagn 2012; 32: 1225-1232.
17. Ehrich M, Deciu C, Zwiefelhofer T, et al,. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: A study in a clinical setting. Am J Obstet Gynecol 2011; 204: e1-e11.
18. Jiang F, Ren J, Chen F, et al,. Noninvasive fetal trisomy (nifty) test: An advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies. BMC Med Genomics 2012; 5: 57.
19. Nicolaides K, Syngelaki A, Ashoor G, et al,. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012; 207: 374.
20. Nicolaides KH, Syngelaki A, Gil M, et al,. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, x, and y. Prenat Diagn 2013; 33: 575-579.
21. Sehnert A, Rhees B, Comstock D, et al,. Optimal detection of fetal chromosomal abnormalities by massively parallel sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011; 57: 1042-1049.
22. Sparks A, Struble CA, Wang ET, et al,. Non-invasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: Evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206: e1-e9.
23. Zimmermann B, Hill M, Gemelos G, et al,. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012; 32: 1233-1241.
24. American College of Obstetricians and Gynecologists Committee on Genetics and the Society for the Maternal Fetal Medicine Publications Committee. Noninvasive prenatal testing for fetal aneuploidy. Number 545, December 2012 [Accessed 8 April 2013] Available from: Http://www.Acog.Org/resources-and- publications/committee-opinions/committee-on-genetics/noninvasive-prenatal- testing-for-fetal-aneuploidy.
25. Benn P, Borell A, Chiu R, et al,. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis April 2013. [Accessed 8 April 2013] Available from: http://ispdhomeorg/public/news/2013/PositionStatementAneuploidy4apr2013pdf
26. Chilberg M,. Sequenom: Diagnostic testing drives investment thesis May 15, 2012. [Accessed 5 April 2013] Available from: http://seekingalpha.Com/ instablog/400846-marty-chilberg/623241-sequenom-diagnostic-testing-drives- investment-thesis.
27. Timmerman L,. Verinata's big day arrives, with prenatal Down syndrome test debut xconomy. [Accessed 8 April 2013] Available from: http://www.Xconomy. Com/san-francisco/2012/02/29/verinatas-big-day-arrives-with-prenatal-down- syndrome-test-debut/. 2012.
28. Walsh J, Goldberg JD,. Fetal aneuploidy detection by maternal plasma DNA sequencing: A technology assessment. Prenat Diagn 2013; 33: 514-520.
29. Ball R, Caughey AB, Malone FD, et al,. First Second Trimester Evaluation of Risk (FASTER) Research Consortium: First-, second-trimester evaluation of risk of Down syndrome. Obstet Gynecol 2007; 110: 10-17.
30. Gekas J, Gagné G, Bujold E, et al,. Comparison of different strategies in prenatal screening for Down's syndrome: Cost effectiveness analysis of computer simulation. BMJ 2009; 338: b138.
31. Song K, Musci T, Caughey AB,. Clinical utility and cost of non-invasive prenatal testing with cfdna analysis in high risk women based on a U.S Population. J Matern Fetal Neonatal Med 2013; 26: 1180-1185.
32. Zimmermann M, Aeberli I, Torresani T, Bürgi H,. Increasing the iodine concentration in the Swiss iodized salt program markedly improved iodine status in pregnant women and children: A 5-y prospective national study. Am J Clin Nutr 2005; 82: 388-392.
33. Australian Government Department of Health and Aging Medicare Benefits Schedule 2013. [Accessed 8 April 2013] Available from: http://www.Health.Gov.Au/ internet/mbsonline/publishing.Nsf/content/medicare-benefits-schedule-mbs-1.
34. Australian Taxation Office. Foreign currency equivalent to $1 Aust -1 July 2012 to 30 June 2013. [Accessed 4 April 2013] Available from http://www.ato.gov.au/Tax-professionals/TP/1-July-2012-to-30-June-2013/.
35. Mujezinovic F, Alfirevic Z,. Procedure-related complications of amniocentesis and chorionic villous sampling: A systematic review. Obstet Gynecol 2007; 110: 687-694.
36. Garfield S, Armstrong S,. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Manag Care Med 2012; 15: 34-41.
37. O'Leary P, Breheny N, Reid G, et al,. Regional variations in prenatal screening across Australia: Stepping towards a national policy framework. Aust N Z J Obstet Gynaecol 2006; 46: 427-432.
38. NIB the costs of having a baby in the private system. [Accessed 8 April 2013] Available from: http://www.Nib.Com.Au/home/documents/having-a-baby-cost- guide.Pdf.
39. Macintosh M, Wald NJ, Chard T, et al,. Correction: The selective miscarriage of Down's syndrome from 10 weeks of pregnancy. Br J Obstet Gynaecol 1996; 103: 1172-1173.
40. Susman M, Amor D, Muggli E, et al,. Using population-based data to predict the impact of introducing noninvasive prenatal diagnosis for Down syndrome. Genet Med 2010; 12: 298-303.
41. Hill M, Fisher J, Chitty LS, Morris S,. Women's and health professionals' preferences for prenatal tests for Down syndrome: A discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests. Genet Med 2012; 14: 905-913.
42. Rowe H, Fisher JR, Quinlivan JA,. Are pregnant Australian women well informed about prenatal genetic screening? A systematic investigation using the multidimensional measure of informed choice. Aust N Z J Obstet Gynaecol 2006; 46: 433-439.
43. Spencer K, Nicolaides KH,. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 2002; 22: 887-889.
44. Drummond MF, Sculpher MJ, Torrance GW, et al,. eds. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press, 2005.